Lite Strategy, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Lite Strategy, Inc. (LITS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.67 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-09-26
- Lite Strategy, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $1.67M, a 85.46% increase from fiscal 2024.
- Lite Strategy, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $901.00K, a 690.35% increase from fiscal 2023.
- Lite Strategy, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $114.00K, a 60.56% increase from fiscal 2022.
- Lite Strategy, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $71.00K, a 1083.33% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-06-30 | $1.67M 10-K · filed 2025-09-26 | |
| 2024-06-30 | $901.00K 10-K · filed 2025-09-26 | -$901.00K 10-K · filed 2024-09-19 |
| 2023-06-30 | $114.00K 10-K · filed 2024-09-19 | |
| 2022-06-30 | $71.00K 10-K · filed 2023-09-26 | |
| 2021-06-30 | $6.00K 10-K · filed 2022-09-08 | |
| 2020-06-30 | $2.00K 10-K · filed 2022-09-08 | |
| 2019-06-30 | -$138.00K 10-K/A · filed 2022-05-23 | |
| 2018-06-30 | $837.00K 10-K · filed 2020-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |